Mi Ran Yun

2.1k total citations
49 papers, 1.4k citations indexed

About

Mi Ran Yun is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Mi Ran Yun has authored 49 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 20 papers in Molecular Biology. Recurrent topics in Mi Ran Yun's work include Lung Cancer Treatments and Mutations (23 papers), Cancer Genomics and Diagnostics (7 papers) and HER2/EGFR in Cancer Research (6 papers). Mi Ran Yun is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Cancer Genomics and Diagnostics (7 papers) and HER2/EGFR in Cancer Research (6 papers). Mi Ran Yun collaborates with scholars based in South Korea, United States and United Kingdom. Mi Ran Yun's co-authors include Byoung Chul Cho, Sun Sik Bae, Chi D. Kim, Min Hee Hong, Kyo Won Seo, Hye Ryun Kim, Seok‐Young Kim, Kyoung‐Ho Pyo, Seong Gu Heo and Won Suk Lee and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

Mi Ran Yun

47 papers receiving 1.4k citations

Peers

Mi Ran Yun
Paula Sotomayor United States
Xuyang Lu United States
Yahya Elshimali United States
Weihua Qiu China
Takafumi Nishimura Japan
Huijuan Qiu China
Claudio Vernieri Italy
Peihua Luo China
Chellappagounder Thangavel United States
Paula Sotomayor United States
Mi Ran Yun
Citations per year, relative to Mi Ran Yun Mi Ran Yun (= 1×) peers Paula Sotomayor

Countries citing papers authored by Mi Ran Yun

Since Specialization
Citations

This map shows the geographic impact of Mi Ran Yun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mi Ran Yun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mi Ran Yun more than expected).

Fields of papers citing papers by Mi Ran Yun

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mi Ran Yun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mi Ran Yun. The network helps show where Mi Ran Yun may publish in the future.

Co-authorship network of co-authors of Mi Ran Yun

This figure shows the co-authorship network connecting the top 25 collaborators of Mi Ran Yun. A scholar is included among the top collaborators of Mi Ran Yun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mi Ran Yun. Mi Ran Yun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, You Won, Jii Bum Lee, Min Hee Hong, et al.. (2024). Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC. Clinical Cancer Research. 30(8). 1582–1594. 10 indexed citations
2.
Lim, Sun Min, Stefanie S. Schalm, Sewon Park, et al.. (2024). BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer. Therapeutic Advances in Medical Oncology. 16. 7 indexed citations
3.
Yun, Mi Ran, et al.. (2024). Novel allosteric glutaminase inhibitors with macrocyclic structure activity relationship analysis (part 2). Bulletin of the Korean Chemical Society. 45(7). 639–644. 1 indexed citations
4.
Yu, Mi Ra, Mi Ran Yun, Jii Bum Lee, et al.. (2023). Abstract 4029: JIN-A04, highly effective tyrosine kinase inhibitor targeting HER2 exon 20 insertion mutations in NSCLC. Cancer Research. 83(7_Supplement). 4029–4029. 1 indexed citations
5.
Lee, You Won, Jae Hwan Kim, YoungJoon Park, et al.. (2022). Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC. Clinical Cancer Research. 29(1). 221–232. 35 indexed citations
6.
Kim, Seok‐Young, Sang-Min Kim, Su-Min Lim, et al.. (2021). Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma. Clinical Cancer Research. 27(15). 4397–4409. 88 indexed citations
7.
Kim, Jae Hwan, Young Seob Kim, Mi Ran Yun, et al.. (2021). Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor. Yonsei Medical Journal. 63(1). 42–42. 10 indexed citations
8.
Yun, Mi Ran, Dong Hwi Kim, Seok‐Young Kim, et al.. (2020). Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(13). 3287–3295. 74 indexed citations
9.
Yun, Jiyeon, Min Hee Hong, Seok‐Young Kim, et al.. (2019). YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 25(8). 2575–2587. 83 indexed citations
10.
Yun, Mi Ran, You Won Lee, Chae Won Park, et al.. (2019). Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer. EMBO Molecular Medicine. 11(12). e10581–e10581. 46 indexed citations
11.
Kang, Han Na, Mi Ran Yun, Hye Ryun Kim, et al.. (2016). ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models. Lung Cancer. 95. 57–64. 6 indexed citations
12.
Pyo, Kyoung‐Ho, Sun Min Lim, Hye Ryun Kim, et al.. (2016). Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK –Positive Human Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(3). 491–500. 20 indexed citations
13.
Kang, Chan Woo, Jinyoung Sohn, Sung‐Moo Kim, et al.. (2015). Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET -Rearranged Lung Adenocarcinoma. Molecular Cancer Therapeutics. 14(10). 2238–2248. 16 indexed citations
14.
15.
Kim, Sun Mi, Mi Ran Yun, Yun Hong, et al.. (2013). Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation. Molecular Cancer Therapeutics. 12(10). 2145–2156. 81 indexed citations
16.
Kim, Won–Ho, et al.. (2011). Visfatin exerts angiogenic effects on human umbilical vein endothelial cells through the mTOR signaling pathway. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1813(5). 763–771. 23 indexed citations
17.
Lee, Seung Joon, Mi Ran Yun, Kyo Won Seo, et al.. (2009). 4-Hydroxynonenal enhances MMP-9 production in murine macrophages via 5-lipoxygenase-mediated activation of ERK and p38 MAPK. Toxicology and Applied Pharmacology. 242(2). 191–198. 39 indexed citations
18.
Yun, Mi Ran, Dong‐Soon Im, Seung Joon Lee, et al.. (2008). 4-Hydroxynonenal enhances CD36 expression on murine macrophages via p38 MAPK-mediated activation of 5-lipoxygenase. Free Radical Biology and Medicine. 46(5). 692–698. 26 indexed citations
19.
Lee, Ji Young, Hye Jin Heo, Mi Ran Yun, et al.. (2006). 4-Hydroxynonenal induces vascular smooth muscle cell apoptosis through mitochondrial generation of reactive oxygen species. Toxicology Letters. 166(3). 212–221. 70 indexed citations
20.
Son, Seok Man, et al.. (2005). Tyrosine kinase-mediated activation of NAD(P)H oxidase enhances proliferative capacity of diabetic vascular smooth muscle cells. Life Sciences. 76(15). 1747–1757. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paula Sotomayor Breakdown of academic impact, for papers by Xuyang Lu Breakdown of academic impact, for papers by Yahya Elshimali Breakdown of academic impact, for papers by Weihua Qiu Breakdown of academic impact, for papers by Takafumi Nishimura Breakdown of academic impact, for papers by Huijuan Qiu Breakdown of academic impact, for papers by Claudio Vernieri Breakdown of academic impact, for papers by Peihua Luo Breakdown of academic impact, for papers by Chellappagounder Thangavel
Rankless by CCL
2026